Siegfried Announces Changes in Senior Management Team

Siegfried has appointed Marianne Späne, currently chief business officer Drug Products, as chief business officer with responsibility for both the Drug Substances and Drug Products divisions of the Swiss contract manufacturing and development organization (CDMO), effective Feb. 1, 2024. Christian Dowdeswell, who previously led the Drug Substance business, has decided to leave Siegfried.

Siegfried also announced the following personnel changes: Klaus Stingl, currently head of the company’s Zofingen site, has been appointed as global head of Business Development and Sales Drug Substances, effective Feb. 1, 2024. Martin Kessler, formerly chief transformation officer at Rentschler, will become CEO of Dinamiqs, a Siegfried subsidiary, as of Mar. 1, 2024, while the current CEO Eduard Ayuso will become chief technology officer.

Manja Boerman, formerly president Cell, Gene and Protein Therapy at Catalent, is to join as a new independent board member of Dinamiqs.

In his new role, Stingl becomes member of Siegfried’s extended executive committee. He joined the company in 2016. Prior to Siegfried, Stingl held several senior positions at Evonik. He holds a Ph.D. in organic chemistry from University of Oldenburg, Germany.

© Siegfried AG
© Siegfried AG

Company

Logo:

Siegfried

Untere Brühlstr. 4
4800 Zofingen
Switzerland

Company contact







Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.